Sierra Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Sierra Sciences's estimated annual revenue is currently $4.2M per year.
- Sierra Sciences's estimated revenue per employee is $155,000
Employee Data
- Sierra Sciences has 27 Employees.
- Sierra Sciences grew their employee count by 13% last year.
Sierra Sciences's People
Name | Title | Email/Phone |
---|
Sierra Sciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $0.3M | 2 | -78% | N/A | N/A |
#3 | $3.5M | 13 | -13% | $18M | N/A |
#4 | $1.4M | 9 | -10% | N/A | N/A |
#5 | $11.8M | 76 | 27% | N/A | N/A |
#6 | $4.2M | 27 | 13% | N/A | N/A |
#7 | $9.3M | 60 | 9% | N/A | N/A |
#8 | $300M | 199 | -13% | $53M | N/A |
#9 | $2.6M | 17 | 6% | N/A | N/A |
#10 | $0.6M | 4 | -20% | N/A | N/A |
What Is Sierra Sciences?
Sierra Sciences, LLC is a company devoted to finding ways to extend our health-spans and life-spans beyond the theoretical maximum of 125 years. Led by founder and president, Dr. Bill Andrews, Sierra Sciences is searching for pharmaceuticals that will induce the production of telomerase in all our cells. Telomerase induction holds the key to living younger, longer. To date, they have screened over 250,000 chemical compounds and natural products, and found over 800 telomerase inducers representing 38 drug families. Sierra Sciences is a private research facility investigating how to induce telomerase expression in all human cells. This could effectively raise the maximum lifespan of humans above 125 years. We are ready to refine our product through medicinal chemistry and then take it to clinical trials. We currently recieve monthly royalties from the sale of Product B, a nutraceutical supplement developed in partnership with us and distributed through Isagenix. Sierra Sciences has made some major discoveries, discoveries that need to be chemically engineered into products; however, we have been stalled. When the bottom dropped out of the stock market in 2008, so went the fortunes of our investors. Dr. Andrews believes that we could have a pharmaceutical ready for human trials within 3 years, given adequate funding. He currently spends much of his time talking with potential investors about this bold, young biotech company.
keywords:N/AN/A
Total Funding
27
Number of Employees
$4.2M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.1M | 27 | N/A | N/A |
#2 | $5.7M | 28 | 8% | N/A |
#3 | $5.7M | 28 | -3% | N/A |
#4 | $5.3M | 28 | 27% | N/A |
#5 | $3.4M | 28 | -20% | $16.2M |